Regentis Biomaterials (NYSE American: RGNT) announced plans to initiate European surgeon training activities in the third quarter of 2026, marking a key step in the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant, beginning at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The training initiative is a central component of Regentis’ European commercialization strategy, supported by a network of Centers of Excellence focused on surgeon education, clinical guidance, and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair. The company believes that expanding physician familiarity with the technology will drive adoption as the product enters broader clinical use.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. It addresses a significant unmet need: according to Regentis, approximately 470,000 cases for cartilage knee repair occur annually in the U.S., where no off-the-shelf treatment is currently available. The European market presents similar opportunities, and the CE Mark approval paves the way for commercialization across member states.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company's initial focus is on orthopedic treatments, with GelrinC as its lead product.
The announcement of surgeon training activities signals a tangible move toward market entry. By equipping surgeons with hands-on experience, Regentis aims to overcome a common barrier to adoption for new medical technologies: lack of familiarity. The Centers of Excellence model will further support this by creating hubs for education and best practice sharing.
For the orthopedic community and patients suffering from knee cartilage lesions, the availability of an off-the-shelf, cell-free implant could represent a significant advancement. Current treatment options often involve complex procedures or multiple surgeries. GelrinC’s single-step approach may offer a simpler and more accessible solution.
Investors should note that forward-looking statements in this release involve risks and uncertainties, including those detailed in the company’s SEC filings. The full press release is available at https://ibn.fm/QOWWK.
